Trials / Unknown
UnknownNCT03688971
Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis
A Phase 2, Randomized, Vehicle and Ketoconazole-Controlled, Evaluator-Blinded, Study to Explore the Efficacy, Pharmacodynamics and Safety of Omiganan 1.75% Topical Gel BID in Patients With Mild to Moderate Facial Seborrheic Dermatitis
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- Maruho Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
To explore the efficacy and pharmacodynamic effects of omiganan topical gel in facial seborrheic dermatitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Omiganan | Omiganan Topical Gel |
| DRUG | Ketoconazole | Ketoconazole Cream |
| DRUG | Placebo | Vehicle |
Timeline
- Start date
- 2018-10-22
- Primary completion
- 2019-12-01
- Completion
- 2019-12-01
- First posted
- 2018-09-28
- Last updated
- 2019-05-01
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT03688971. Inclusion in this directory is not an endorsement.